638 related articles for article (PubMed ID: 15755676)
21. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
22. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.
Engelender S; Kaminsky Z; Guo X; Sharp AH; Amaravi RK; Kleiderlein JJ; Margolis RL; Troncoso JC; Lanahan AA; Worley PF; Dawson VL; Dawson TM; Ross CA
Nat Genet; 1999 May; 22(1):110-4. PubMed ID: 10319874
[TBL] [Abstract][Full Text] [Related]
23. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
24. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M
Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133
[TBL] [Abstract][Full Text] [Related]
25. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
[TBL] [Abstract][Full Text] [Related]
26. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line.
Kohno R; Sawada H; Kawamoto Y; Uemura K; Shibasaki H; Shimohama S
Biochem Biophys Res Commun; 2004 May; 318(1):113-8. PubMed ID: 15110760
[TBL] [Abstract][Full Text] [Related]
27. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
28. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire-Zeiss KA; Short DW; Federoff HJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
[TBL] [Abstract][Full Text] [Related]
29. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
30. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
[TBL] [Abstract][Full Text] [Related]
31. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
32. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
Yavich L; Oksman M; Tanila H; Kerokoski P; Hiltunen M; van Groen T; Puoliväli J; Männistö PT; García-Horsman A; MacDonald E; Beyreuther K; Hartmann T; Jäkälä P
Neurobiol Dis; 2005 Nov; 20(2):303-13. PubMed ID: 16242637
[TBL] [Abstract][Full Text] [Related]
33. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
34. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.
Nieto M; Gil-Bea FJ; Dalfó E; Cuadrado M; Cabodevilla F; Sánchez B; Catena S; Sesma T; Ribé E; Ferrer I; Ramírez MJ; Gómez-Isla T
Neurobiol Aging; 2006 Jun; 27(6):848-56. PubMed ID: 16006012
[TBL] [Abstract][Full Text] [Related]
35. Gene dosage and pathogenesis of Parkinson's disease.
Eriksen JL; Przedborski S; Petrucelli L
Trends Mol Med; 2005 Mar; 11(3):91-6. PubMed ID: 15760766
[TBL] [Abstract][Full Text] [Related]
36. Alpha-synuclein and transgenic mouse models.
Fernagut PO; Chesselet MF
Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
[TBL] [Abstract][Full Text] [Related]
37. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
38. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
39. Does cellular iron dysregulation play a causative role in Parkinson's disease?
Kaur D; Andersen J
Ageing Res Rev; 2004 Jul; 3(3):327-43. PubMed ID: 15231240
[TBL] [Abstract][Full Text] [Related]
40. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors.
Krenz A; Falkenburger BH; Gerhardt E; Drinkut A; Schulz JB
J Neurochem; 2009 Jan; 108(1):139-46. PubMed ID: 19094062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
